Tissue Regenix Group PLC Appointment of CFO (5075T)
04 July 2018 - 4:00PM
UK Regulatory
TIDMTRX
RNS Number : 5075T
Tissue Regenix Group PLC
04 July 2018
Tissue Regenix Group plc
Appointment of CFO
Leeds, 04 July 2018 - Tissue Regenix Group (AIM:TRX) ("Tissue
Regenix" or "The Group") the regenerative medical devices company,
today announces the appointment of Gareth Hywel Jones as Chief
Financial Officer (CFO). He will join the Group as CFO, Company
Secretary and as an Executive Director on the Board on 30 November
2018.
Mr Jones, who will join the Group from Applied Graphene
Materials plc (AGM), is an experienced CFO, bringing significant
operational, high technology manufacturing and strategic financial
expertise gained through roles in UK and US listed businesses as
well as private equity.
Current interim CFO, Paul Below, will remain with The Group to
facilitate an orderly hand-over.
Steve Couldwell, CEO Tissue Regenix Group, commented: "We are
delighted to announce the appointment of Gareth as our Chief
Financial Officer. After an extensive recruitment process, Gareth's
proven experience of implementing operational enhancements,
divisional business unit management, profit improvement initiatives
and strategic commercial planning, in both UK and US quoted
companies, will significantly strengthen our leadership team. I
look forward to welcoming Gareth to the Group in November."
Gareth Jones, CFO - Designate for Tissue Regenix, commented:
"Tissue Regenix is at an exciting inflection point in terms of
executing against its commercial growth strategy. With tangible and
growing traction in the US markets and multiple EU product launches
expected, I look forward to working with the executive team and
Board as the Company continues to deliver strong organic growth
from its innovative products."
Mr Jones qualified as a Chartered Accountant with
Pricewaterhouse Coopers in 1993.
Full details of Mr Jones' (aged 50) current and past
directorships within the last five years are provided below. It is
intended that Mr Jones will step down from all other Directorships
upon commencement of his position within The Group.
Current Directorships
Applied Graphene Materials plc, Chief Financial Officer, April
2017 - Present
Applied Graphene Materials UK Limited
Past Directorships
Gardner Denver Group Services Limited, Finance Director of Emco
Wheaton Division, September 2013-March 2017
Vireol Bio-Industries plc, Vireol Limited, Finance and
Commercial Director October 2006-September 2013
Gareth Jones has no shareholding in the Company. It is intended
that the Company will, on or as soon as possible following his
appointment grant Gareth options over new ordinary shares in the
Company.
There is no further information to be disclosed in accordance
with the requirements of Schedule Two paragraph (g) of the AIM
rules.
For more Information:
Tissue Regenix Group plc Tel: 0330 430 3073 /
Caitlin Pearson Head of Communications 07920272 441
----------------------------------------- ---------------------
Jefferies International Ltd Tel: 020 7029 8000
Simon Hardy / Christopher Binks
----------------------------------------- ---------------------
FTI Consulting Tel: 0203 727 1000
Brett Pollard / Mo Noonan/ Mary Whittow
========================================= =====================
About Tissue Regenix
Tissue Regenix is a leading medical devices company in the field
of regenerative medicine. Tissue Regenix was formed in 2006 when it
was spun-out from the University of Leeds, UK. The company's
patented decellularisation ('dCELL(R) ') technology removes DNA and
other cellular material from animal and human soft tissue leaving
an acellular tissue scaffold which is not rejected by the patient's
body and can then be used to repair diseased or worn out body
parts. Current applications address many critical clinical needs
such as sports medicine, heart valve replacement and wound
care.
In November 2012 Tissue Regenix Group plc set up a subsidiary
company in the United States - 'Tissue Regenix Wound Care Inc.',
January 2016 saw the establishment of joint venture GBM-V, a multi-
tissue bank based in Rostock, Germany.
In August 2017 Tissue Regenix acquired CellRight Technologies(R)
, a biotech company that specializes in regenerative medicine and
is dedicated to the development of innovative osteoinductive and
wound care scaffolds that enhance healing opportunities of defects
created by trauma and disease. CellRight's human osteobiologics may
be used in spine, trauma, general orthopedic, foot & ankle,
dental, and sports medicine surgical procedures.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOAUGUMUMUPRPPW
(END) Dow Jones Newswires
July 04, 2018 02:00 ET (06:00 GMT)
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Apr 2024 to May 2024
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From May 2023 to May 2024